Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SPRINT-type BP control provides up to 3 years of additional life

Key clinical point: New SPRINT analysis provides clinicians with a better way to discuss BP control with patients.

Major finding: A middle-aged hypertensive patient at high cardiovascular risk can expect to gain an additional 3 years of life through intensive rather than less aggressive BP lowering.

Study details: This was a secondary analysis of the SPRINT trial, which randomized 9,361 high-cardiovascular-risk hypertensive patients to a target systolic BP of less than either 120 or 140 mm Hg.

Disclosures: The study presenter reported that he receives research support from/and or serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer, Boehringer Ingelheim, and Relypsa.


Vaduganathan M et al. AHA 2019, Abstract MDP233.